Nat. Immunol. 18, 74–85 (2017); published online 28 November 2016; corrected after print 23 January 2017
In the version of this article initially published, the label for third bar from the left in Figure 4f ('Anti-IL-6α') was incorrect; the correct label is 'Anti-IL-6Rα'. Also, in the legend for Figure 4f, the description of the treatment conditions for middle four bars ('medium alone, or LPS and anti-IL-6 (MR16-1 or polyclonal antibody), anti-IL-6R (mAb#8)') was incorrect; the correct description is 'LPS alone (Medium), or LPS and anti-IL-6Rα (MR16-1), anti-IL-6 (polyclonal antibody or mAb#8)'. The error has been corrected for the print, PDF and HTML versions of this article.
The online version of the original article can be found at 10.1038/ni.3632
About this article
Disruption of FOXP3–EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation
Cellular and Molecular Gastroenterology and Hepatology (2019)
Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells
Frontiers in Immunology (2017)